Amazon quietly scrapped a four-year-old project to develop a fertility-tracking device and smartphone app
Amazon’s 2020 acquisition of bluDiagnostics, a startup that was developing a device that measured the levels of estradiol and progesterone, two of the hormones responsible for fertility in women, from saliva samples, gave rise to the project, which was known by the codename “Encore.”
According to the report, Amazon intended to introduce the product this year; however, the team of approximately 100 team members encountered technical difficulties. Encore was a component of Amazon’s Grand Challenge initiative, a clandestine laboratory renowned for undertaking ambitious or moonshot projects like cancer research.
Since 2022, Andy Jassy, the organization’s CEO, has implemented a cost-cutting strategy. He terminated numerous experimental projects, such as a virtual tour product and an AR headset for meetings, and eliminated 27,000 positions.
In the next few years, AI's insatiable need for energy is likely to grow, which could cause data centers to…
The Usual (USUAL) token has been listed on Binance Launchpool, and pre-market trading will commence shortly. Market optimism has been…
Amazon One Medical is adding more telehealth services with the start of low-cost treatment plans and medication delivery for a…
Franklin Templeton has extended its Benji tokenization platform to the Ethereum network following its previous launches on Aptos, Avalanche, Arbitrum,…
Latest data shows US PPI inflation at 2.4%, above forecast, dampening investor sentiment due to its potential impact on the…
DeFi's increasing accessibility is seen by PancakeSwap's new Telegram bot, which allows users to swap over 3,000 tokens from the…